Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Paul Richardson
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Concepts & Ideas
Physiology
Phenomena
Procedures
Anatomy
Sign-in to see full Profile
Network (preview)
83
Anderson, Kenneth
52
Hideshima, Teru
44
Mitsiades, Constantine
34
Munshi, Nikhil
28
Chauhan, Dharminder
19
Mitsiades, Nicholas
19
podar, klaus
17
Schlossman, Robert
15
Raje, Noopur
12
Irwin, David
12
Esseltine, Dixie
11
Jagannath, Sundar
10
Yasui, Hiroshi
9
Tai, Yu-Tzu
9
Ishitsuka, Kenji
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Paul Richardson (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Negri Joseph M; McMillin Douglas W; Delmore Jake; Mitsiades Nicholas; Hayden Patrick; Klippel Steffen; Hideshima Teru; Chauhan Dharminder; Munshi Nikhil C; Buser Carolyn A; Pollard John; Richardson Paul G; Anderson Kenneth C; Mitsiades Constantine S
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
British journal of haematology 2009;147(5):672-6.
-
2009: Kumar Shaji; Giralt Sergio; Stadtmauer Edward A; Harousseau Jean L; Palumbo Antonio; Bensinger William; Comenzo Raymond L; Lentzsch Suzanne; Munshi Nikhil; Niesvizky Ruben; San Miguel Jesus; Ludwig Heinz; Bergsagel Leif; Blade Joan; Lonial Sagar; Anderson Kenneth C; Tosi Patrizia; Sonneveld Pieter; Sezer Orhan; Vesole David; Cavo Michele; Einsele Hermann; Richardson Paul G; Durie Brian G M; Rajkumar S Vincent;
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Blood 2009;114(9):1729-35.
-
2009: McMillin Douglas W; Ooi Melissa; Delmore Jake; Negri Joseph; Hayden Patrick; Mitsiades Nicolas; Jakubikova Jana; Maira Sauveur-Michel; Garcia-Echeverria Carlos; Schlossman Robert; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C; Mitsiades Constantine S
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Cancer research 2009;69(14):5835-42.
-
2009: Richardson Paul G; Xie Wanling; Mitsiades Constantine; Chanan-Khan Asher A; Lonial Sagar; Hassoun Hani; Avigan David E; Oaklander Anne Louise; Kuter David J; Wen Patrick Y; Kesari Santosh; Briemberg Hannah R; Schlossman Robert L; Munshi Nikhil C; Heffner L Thompson; Doss Deborah; Esseltine Dixie-Lee; Weller Edie; Anderson Kenneth C; Amato Anthony A
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3518-25.
-
2009: Hideshima Teru; Ikeda Hiroshi; Chauhan Dharminder; Okawa Yutaka; Raje Noopur; Podar Klaus; Mitsiades Constantine; Munshi Nikhil C; Richardson Paul G; Carrasco Ruben D; Anderson Kenneth C
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Blood 2009;114(5):1046-52.
-
2009: Laubach Jacob P; Mitsiades Constantine S; Roccaro Aldo M; Ghobrial Irene M; Anderson Kenneth C; Richardson Paul G
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Leukemia & lymphoma 2009;50(5):694-702.
-
2009: Hideshima Teru; Chauhan Dharminder; Kiziltepe Tanyel; Ikeda Hiroshi; Okawa Yutaka; Podar Klaus; Raje Noopur; Protopopov Alexei; Munshi Nikhil C; Richardson Paul G; Carrasco Ruben D; Anderson Kenneth C
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.
Blood 2009;113(21):5228-36.
-
2009: Mitsiades Constantine S; Hideshima Teru; Chauhan Dharminder; McMillin Douglas W; Klippel Steffen; Laubach Jacob P; Munshi Nikhil C; Anderson Kenneth C; Richardson Paul G
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Seminars in hematology 2009;46(2):166-75.
-
2009: Podar Klaus; Tai Yu-Tzu; Hideshima Teru; Vallet Sonia; Richardson Paul G; Anderson Kenneth C
Emerging therapies for multiple myeloma.
Expert opinion on emerging drugs 2009;14(1):99-127.
-
2009: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Bladé Joan; Boccadoro Mario; Cavenagh Jamie D; Boral Anthony L; Esseltine Dixie-Lee; Wen Patrick Y; Amato Anthony A; Anderson Kenneth C; San Miguel Jesus
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
British journal of haematology 2009;144(6):895-903.
-
2008: Lee Stephanie J; Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; San Miguel Jesús-F; Crawford Bruce; Massaro Joseph; Dhawan Ravinder; Gupta Sanjay; Anderson Kenneth C
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
British journal of haematology 2008;143(4):511-9.
-
2008: Jagannath Sundar; Barlogie Bart; Berenson James R; Siegel David S; Irwin David; Richardson Paul G; Niesvizky Ruben; Alexanian Raymond; Limentani Steven A; Alsina Melissa; Esseltine Dixie-Lee; Anderson Kenneth C
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
British journal of haematology 2008;143(4):537-40.
-
2008: Roccaro Aldo M; Ghobrial Irene M; Blotta Simona; Treon Steven P; Malagola Michele; Anderson Kenneth C; Richardson Paul G; Russo Domenico
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
Biologics : targets & therapy 2008;2(3):419-31.
-
2008: Mitsiades Constantine S; Ocio Enrique M; Pandiella Atanasio; Maiso Patricia; Gajate Consuelo; Garayoa Mercedes; Vilanova David; Montero Juan Carlos; Mitsiades Nicholas; McMullan Ciaran J; Munshi Nikhil C; Hideshima Teru; Chauhan Dharminder; Aviles Pablo; Otero Gabriel; Faircloth Glynn; Mateos M Victoria; Richardson Paul G; Mollinedo Faustino; San-Miguel Jesus F; Anderson Kenneth C
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Cancer research 2008;68(13):5216-25.
-
2008: Richardson Paul G; Mitsiades Constantine; Schlossman Robert; Ghobrial Irene; Hideshima Teru; Munshi Nikhil; Anderson Kenneth C
Bortezomib in the front-line treatment of multiple myeloma.
Expert review of anticancer therapy 2008;8(7):1053-72.
-
2008: Munshi Nikhil C; Mitsiades Constantine; Richardson Paul G; Anderson Kenneth C
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.
Nature clinical practice. Oncology 2008;5(7):374-5.
-
2008: Hideshima Teru; Raje Noopur; Richardson Paul G; Anderson Kenneth C
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.
Therapeutics and clinical risk management 2008;4(1):129-36.
-
2008: Ho V T; Revta C; Richardson P G
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
Bone marrow transplantation 2008;41(3):229-37.
-
2007: Mitsiades Constantine S; Hayden Patrick J; Anderson Kenneth C; Richardson Paul G
From the bench to the bedside: emerging new treatments in multiple myeloma.
Best practice & research. Clinical haematology 2007;20(4):797-816.
-
2007: Podar Klaus; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
The malignant clone and the bone-marrow environment.
Best practice & research. Clinical haematology 2007;20(4):597-612.
-
2007: Hayden Patrick J; Mitsiades Constantine S; Anderson Kenneth C; Richardson Paul G
Novel therapies in myeloma.
Current opinion in hematology 2007;14(6):609-15.
-
2007: Richardson Paul G; Sonneveld Pieter; Schuster Michael; Irwin David; Stadtmauer Edward; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Miguel Jesus San; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Alsina Melissa; Rajkumar S Vincent; Lacy Martha; Jakubowiak Andrzej; Dalton William; Boral Anthony; Esseltine Dixie-Lee; Schenkein David; Anderson Kenneth C
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Blood 2007;110(10):3557-60.
-
2007: Breitkreutz Iris; Raab Marc S; Vallet Sonia; Hideshima Teru; Raje Noopur; Chauhan Dharminder; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
British journal of haematology 2007;139(1):55-63.
-
2007: Hideshima Teru; Catley Laurence; Raje Noopur; Chauhan Dharminder; Podar Klaus; Mitsiades Constantine; Tai Yu-Tzu; Vallet Sonia; Kiziltepe Tanyel; Ocio Enrique; Ikeda Hiroshi; Okawa Yutaka; Hideshima Hiromasa; Munshi Nikhil C; Yasui Hiroshi; Richardson Paul G; Anderson Kenneth C
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
British journal of haematology 2007;138(6):783-91.
-
2007: Mitsiades Constantine S; Mitsiades Nicholas S; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
Journal of cellular biochemistry 2007;101(4):950-68.
-
2007: Munshi Nikhil C; Mitsiades Constantine S; Richardson Paul G; Anderson Kenneth C
Does maintenance therapy with thalidomide benefit patients with multiple myeloma?
Nature clinical practice. Oncology 2007;4(7):394-5.
-
2007: Richardson Paul G; Mitsiades Constantine; Schlossman Robert; Munshi Nikhil; Anderson Kenneth
New drugs for myeloma.
The oncologist 2007;12(6):664-89.
-
2007: Ho Vincent T; Linden Erica; Revta Carolyn; Richardson Paul G
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
Seminars in thrombosis and hemostasis 2007;33(4):373-88.
-
2007: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; San Miguel Jesús-F; Cavenagh Jamie D; Anderson Kenneth C
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
British journal of haematology 2007;137(5):429-35.
-
2007: Podar Klaus; Richardson Paul G; Chauhan Dharminder; Anderson Kenneth C
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Expert review of anticancer therapy 2007;7(4):551-66.
-
2007: Yasui H; Hideshima T; Ikeda H; Ocio E M; Kiziltepe T; Vallet S; Okawa Y; Neri P; Sukhdeo K; Podar K; Chauhan D; Richardson P G; Raje N; Carrasco D R; Anderson K C
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(3):535-40.
-
2007: Richardson Paul G; Hideshima Teru; Mitsiades Constantine; Anderson Kenneth C
The emerging role of novel therapies for the treatment of relapsed myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):149-62.
-
2007: Koreth John; Cutler Corey S; Djulbegovic Benjamin; Behl Rajesh; Schlossman Robert L; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C; Soiffer Robert J; Alyea Edwin P
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2007;13(2):183-96.
-
2007: Yasui Hiroshi; Hideshima Teru; Ikeda Hiroshi; Jin Janice; Ocio Enrique M; Kiziltepe Tanyel; Okawa Yutaka; Vallet Sonia; Podar Klaus; Ishitsuka Kenji; Richardson Paul G; Pargellis Chris; Moss Neil; Raje Noopur; Anderson Kenneth C
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
British journal of haematology 2007;136(3):414-23.
-
2007: Jagannath S; Richardson P G; Sonneveld P; Schuster M W; Irwin D; Stadtmauer E A; Facon T; Harousseau J-L; Cowan J M; Anderson K C
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(1):151-7.
-
2006: Richardson Paul G; Mitsiades Constantine; Ghobrial Irene; Anderson Kenneth
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Current opinion in oncology 2006;18(6):598-608.
-
2006: Richardson Paul G; Blood Emily; Mitsiades Constantine S; Jagannath Sundar; Zeldenrust Steven R; Alsina Melissa; Schlossman Robert L; Rajkumar S Vincent; Desikan K Raman; Hideshima Teru; Munshi Nikhil C; Kelly-Colson Kathleen; Doss Deborah; McKenney Mary L; Gorelik Svetlana; Warren Diane; Freeman Andrea; Rich Rebecca; Wu Anfang; Olesnyckyj Marta; Wride Kenton; Dalton William S; Zeldis Jerome; Knight Robert; Weller Edie; Anderson Kenneth C
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood 2006;108(10):3458-64.
-
2006: Yasui Hiroshi; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Recent advances in the treatment of Multiple Myeloma.
Current pharmaceutical biotechnology 2006;7(5):381-93.
-
2006: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Current drug targets 2006;7(10):1341-7.
-
2006: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Lenalidomide in multiple myeloma.
Expert review of anticancer therapy 2006;6(8):1165-73.
-
2006: Jagannath Sundar; Richardson Paul G; Barlogie Bart; Berenson James R; Singhal Seema; Irwin David; Srkalovic Gordan; Schenkein David P; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Haematologica 2006;91(7):929-34.
-
2006: Mitsiades Constantine S; Mitsiades Nicholas S; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.
European journal of cancer (Oxford, England : 1990) 2006;42(11):1564-73.
-
2006: Richardson Paul G; Briemberg Hannah; Jagannath Sundar; Wen Patrick Y; Barlogie Bart; Berenson James; Singhal Seema; Siegel David S; Irwin David; Schuster Michael; Srkalovic Gordan; Alexanian Raymond; Rajkumar S Vincent; Limentani Steven; Alsina Melissa; Orlowski Robert Z; Najarian Kevin; Esseltine Dixie; Anderson Kenneth C; Amato Anthony A
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3113-20.
-
2006: Hideshima Teru; Catley Laurence; Yasui Hiroshi; Ishitsuka Kenji; Raje Noopur; Mitsiades Constantine; Podar Klaus; Munshi Nikhil C; Chauhan Dharminder; Richardson Paul G; Anderson Kenneth C
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Blood 2006;107(10):4053-62.
-
2006: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David H; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Anderson Kenneth C
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Cancer 2006;106(6):1316-9.
-
2006: Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Current therapeutic uses of lenalidomide in multiple myeloma.
Expert opinion on investigational drugs 2006;15(2):171-9.
-
2006: Yasui Hiroshi; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
British journal of haematology 2006;132(4):385-97.
-
2006: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Kung Andrew L; Davies Faith E; Morgan Gareth; Akiyama Masaharu; Shringarpure Reshma; Munshi Nikhil C; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Rosen Neal S; Anderson Kenneth C
Antimyeloma activity of heat shock protein-90 inhibition.
Blood 2006;107(3):1092-100.
-
2006: Roccaro Aldo Maria; Hideshima Teru; Raje Noopur; Kumar Shaji; Ishitsuka Kenji; Yasui Hiroshi; Shiraishi Norihiko; Ribatti Domenico; Nico Beatrice; Vacca Angelo; Dammacco Franco; Richardson Paul Gerard; Anderson Kenneth Carl
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Cancer research 2006;66(1):184-91.
-
2005: Richardson Paul G; Schlossman Robert; Hideshima Teru; Anderson Kenneth C
New treatments for multiple myeloma.
Oncology (Williston Park, N.Y.) 2005;19(14):1781-92; discussion 1792, 1795-7.
-
2005: Berenson James R; Jagannath Sundar; Barlogie Bart; Siegel David T; Alexanian Raymond; Richardson Paul G; Irwin David; Alsina Melissa; Rajkumar S Vincent; Srkalovic Gordon; Singhal Seema; Limentani Steven; Niesvizky Ruben; Esseltine Dixie L; Trehu Elizabeth; Schenkein David P; Anderson Kenneth
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer 2005;104(10):2141-8.
-
2005: Richardson Paul Gerard Guy; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Hideshima Teru; Xiao Hugh; Esseltine Dixie; Schenkein David; Anderson Kenneth C;
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood 2005;106(9):2977-81.
-
2005: Richardson Paul G; Schlossman Robert; Mitsiades Constantine; Hideshima Teru; Munshi Nikhil; Anderson Kenneth
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Clinical lymphoma & myeloma 2005;6(2):84-8.
-
2005: Yasui Hiroshi; Hideshima Teru; Raje Noopur; Roccaro Aldo M; Shiraishi Norihiko; Kumar Shaji; Hamasaki Makoto; Ishitsuka Kenji; Tai Yu-Tzu; Podar Klaus; Catley Laurence; Mitsiades Constantine S; Richardson Paul G; Albert Rainer; Brinkmann Volker; Chauhan Dharminder; Anderson Kenneth C
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Cancer research 2005;65(16):7478-84.
-
2005: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Expert review of anticancer therapy 2005;5(3):465-76.
-
2005: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; San-Miguel Jesus F; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Dalton William S; Boral Anthony L; Esseltine Dixie L; Porter Jane B; Schenkein David; Anderson Kenneth C;
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
The New England journal of medicine 2005;352(24):2487-98.
-
2005: Gribben John G; Ryan David P; Boyajian Richard; Urban Robert G; Hedley Mary L; Beach Kathleen; Nealon Patrick; Matulonis Ursula; Campos Susana; Gilligan Timothy D; Richardson Paul G; Marshall Blossom; Neuberg Donna; Nadler Lee M
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4430-6.
-
2005: Hamasaki Makoto; Hideshima Teru; Tassone Pierfrancesco; Neri Paola; Ishitsuka Kenji; Yasui Hiroshi; Shiraishi Norihiko; Raje Noopur; Kumar Shaji; Picker Donald H; Jacob Gary S; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Blood 2005;105(11):4470-6.
-
2005: Richardson Paul G; Mitsiades Constantine
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Future oncology (London, England) 2005;1(2):161-71.
-
2005: Hideshima Teru; Chauhan Dharminder; Ishitsuka Kenji; Yasui Hiroshi; Raje Noopur; Kumar Shaji; Podar Klaus; Mitsiades Constantine; Hideshima Hiromasa; Bonham Lynn; Munshi Nikhil C; Richardson Paul G; Singer Jack W; Anderson Kenneth C
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Oncogene 2005;24(19):3121-9.
-
2005: Jagannath Sundar; Barlogie Bart; Berenson James R; Singhal Seema; Alexanian Raymond; Srkalovic Gordan; Orlowski Robert Z; Richardson Paul G; Anderson Jessica; Nix Darrell; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer 2005;103(6):1195-200.
-
2005: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Proteasome inhibition in the treatment of cancer.
Cell cycle (Georgetown, Tex.) 2005;4(2):290-6.
-
2005: Lee S J; Loberiza F R; Antin J H; Kirkpatrick T; Prokop L; Alyea E P; Cutler C; Ho V T; Richardson P G; Schlossman R L; Fisher D C; Logan B; Soiffer R J
Routine screening for psychosocial distress following hematopoietic stem cell transplantation.
Bone marrow transplantation 2005;35(1):77-83.
-
2005: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibitors as therapeutics.
Essays in biochemistry 2005;41():205-18.
-
2005: Richardson Paul G; Mitsiades Constantine S; Hideshima Teru; Anderson Kenneth C
Novel biological therapies for the treatment of multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):619-34.
-
2004: Hideshima Teru; Podar Klaus; Chauhan Dharminder; Ishitsuka Kenji; Mitsiades Constantine; Tai Yu-Tzu; Hamasaki Makoto; Raje Noopur; Hideshima Hiromasa; Schreiner George; Nguyen Aaron N; Navas Tony; Munshi Nikhil C; Richardson Paul G; Higgins Linda S; Anderson Kenneth C
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Oncogene 2004;23(54):8766-76.
-
2004: Le Gouill Steven; Podar Klaus; Amiot Martine; Hideshima Teru; Chauhan Dharminder; Ishitsuka Kenji; Kumar Shaji; Raje Noopur; Richardson Paul G; Harousseau Jean-Luc; Anderson Kenneth C
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.
Blood 2004;104(9):2886-92.
-
2004: Podar Klaus; Shringarpure Reshma; Tai Yu-Tzu; Simoncini Melissa; Sattler Martin; Ishitsuka Kenji; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Cancer research 2004;64(20):7500-6.
-
2004: Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson P G; Niesvizky R; Alexanian R; Limentani S A; Alsina M; Adams J; Kauffman M; Esseltine D-L; Schenkein D P; Anderson K C
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
British journal of haematology 2004;127(2):165-72.
-
2004: Richardson Paul G
A review of the proteasome inhibitor bortezomib in multiple myeloma.
Expert opinion on pharmacotherapy 2004;5(6):1321-31.
-
2004: Podar Klaus; Catley Laurence P; Tai Yu-Tzu; Shringarpure Reshma; Carvalho Pedro; Hayashi Toshiaki; Burger Renate; Schlossman Robert L; Richardson Paul G; Pandite Lini N; Kumar Rakesh; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Blood 2004;103(9):3474-9.
-
2004: LeBlanc Richard; Hideshima Teru; Catley Laurence P; Shringarpure Reshma; Burger Renate; Mitsiades Nicholas; Mitsiades Constantine; Cheema Puneet; Chauhan Dharminder; Richardson Paul G; Anderson Kenneth C; Munshi Nikhil C
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
Blood 2004;103(5):1787-90.
-
2004: Richardson Paul G; Hideshima Teru; Mitsiades Constantine; Anderson Kenneth
Proteasome inhibition in hematologic malignancies.
Annals of medicine 2004;36(4):304-14.
-
2003: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Podar Klaus; Akiyama Masaharu; Mitsiades Constantine; MItsiades Nicholas; Gong Baoqing; Bonham Lynn; de Vries Peter; Munshi Nikhil; Richardson Paul G; Singer Jack W; Anderson Kenneth C
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Cancer research 2003;63(23):8428-36.
-
2003: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Akiyama Masaharu; Mitsiades Nicholas; Mitsiades Constantine; Podar Klaus; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Oncogene 2003;22(52):8386-93.
-
2003: Richardson Paul G; Anderson Kenneth C
Bortezomib: a novel therapy approved for multiple myeloma.
Clinical advances in hematology & oncology : H&O 2003;1(10):596-600.
-
2003: Wadleigh Martha; Richardson Paul G; Zahrieh David; Lee Stephanie J; Cutler Corey; Ho Vincent; Alyea Edwin P; Antin Joseph H; Stone Richard M; Soiffer Robert J; DeAngelo Daniel J
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Blood 2003;102(5):1578-82.
-
2003: Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Targeting proteasome inhibition in hematologic malignancies.
Reviews in clinical and experimental hematology 2003;7(2):191-204.
-
2003: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Alexanian Raymond; Siegel David; Orlowski Robert Z; Kuter David; Limentani Steven A; Lee Stephanie; Hideshima Teru; Esseltine Dixie-Lee; Kauffman Michael; Adams Julian; Schenkein David P; Anderson Kenneth C
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
-
2003: Maecker Britta; Anderson Karen S; von Bergwelt-Baildon Michael S; Weller Edie; Vonderheide Robert H; Richardson Paul G; Schlossman Robert L; Menezes Isaura A; Xia Zhinan; Munshi Nikhil C; Anderson Kenneth C; Nadler Lee M; Schultze Joachim L
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.
British journal of haematology 2003;121(6):842-8.
-
2003: Mitsiades Nicholas; Mitsiades Constantine S; Richardson Paul G; McMullan Ciaran; Poulaki Vassiliki; Fanourakis Galinos; Schlossman Robert; Chauhan Dharminder; Munshi Nikhil C; Hideshima Teru; Richon Victoria M; Marks Paul A; Anderson Kenneth C
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Blood 2003;101(10):4055-62.
-
2003: Mitsiades Constantine S; Mitsiades Nicholas; Richardson Paul G; Treon Steven P; Anderson Kenneth C
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Seminars in oncology 2003;30(2):309-12.
-
2003: Mitsiades Nicholas; Mitsiades Constantine S; Richardson Paul G; Poulaki Vassiliki; Tai Yu-Tzu; Chauhan Dharminder; Fanourakis Galinos; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Schlossman Robert; Munshi Nikhil C; Hideshima Teru; Anderson Kenneth C
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Blood 2003;101(6):2377-80.
-
2002: Richardson Paul G; Murakami Carol; Jin Zhezhen; Warren Diane; Momtaz Parisa; Hoppensteadt Deborah; Elias Anthony D; Antin Joseph H; Soiffer Robert; Spitzer Thomas; Avigan David; Bearman Scott I; Martin Paul L; Kurtzberg Joanne; Vredenburgh James; Chen Allen R; Arai Sally; Vogelsang Georgia; McDonald George B; Guinan Eva C
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
Blood 2002;100(13):4337-43.
-
2002: Richardson Paul G; Schlossman Robert L; Weller Edie; Hideshima Teru; Mitsiades Constantine; Davies Faith; LeBlanc Richard; Catley Laurence P; Doss Deborah; Kelly Kathleen; McKenney Mary; Mechlowicz Julie; Freeman Andrea; Deocampo Reggie; Rich Rebecca; Ryoo Joan J; Chauhan Dharminder; Balinski Kathe; Zeldis Jerome; Anderson Kenneth C
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Blood 2002;100(9):3063-7.
-
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Fanourakis Galinos; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Treon Steven P; Munshi Nikhil C; Richardson Paul G; Hideshima Teru; Anderson Kenneth C
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(22):14374-9.
-
2002: Lin Boris; Podar Klaus; Gupta Deepak; Tai Yu-Tzu; Li Sigui; Weller Edie; Hideshima Teru; Lentzsch Suzanne; Davies Faith; Li Cheng; Weisberg Ellen; Schlossman Robert L; Richardson Paul G; Griffin James D; Wood Jeanette; Munshi Nikhil C; Anderson Kenneth C
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2002;62(17):5019-26.
-
2002: LeBlanc Richard; Catley Laurence P; Hideshima Teru; Lentzsch Suzanne; Mitsiades Constantine S; Mitsiades Nicholas; Neuberg Donna; Goloubeva Olga; Pien Christine S; Adams Julian; Gupta Deepak; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Cancer research 2002;62(17):4996-5000.
-
2002: Mitsiades Constantine S; Mitsiades Nicholas; Poulaki Vassiliki; Schlossman Robert; Akiyama Masaharu; Chauhan Dharminder; Hideshima Teru; Treon Steven P; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Oncogene 2002;21(37):5673-83.
-
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Richardson Paul G; Hideshima Teru; Munshi Nikhil C; Treon Steven P; Anderson Kenneth C
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Blood 2002;99(12):4525-30.
-
2001: Davies F E; Raje N; Hideshima T; Lentzsch S; Young G; Tai Y T; Lin B; Podar K; Gupta D; Chauhan D; Treon S P; Richardson P G; Schlossman R L; Morgan G J; Muller G W; Stirling D I; Anderson K C
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Blood 2001;98(1):210-6.
-
2001: Burstein H J; Kuter I; Campos S M; Gelman R S; Tribou L; Parker L M; Manola J; Younger J; Matulonis U; Bunnell C A; Partridge A H; Richardson P G; Clarke K; Shulman L N; Winer E P
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2722-30.
-
1998: Richardson P G; Elias A D; Krishnan A; Wheeler C; Nath R; Hoppensteadt D; Kinchla N M; Neuberg D; Waller E K; Antin J H; Soiffer R; Vredenburgh J; Lill M; Woolfrey A E; Bearman S I; Iacobelli M; Fareed J; Guinan E C
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
Blood 1998;92(3):737-44.
Sign-in to see more
